Hematopoietic cell transplantation (HCT) is used for treatment of hematopoietic diseases. Assessment of T-and B-cell reconstitution after HCT is crucial because poor immune recovery has a major effect on the clinical course. In this study, we retrospectively analyzed T-cell receptor excision circles (TRECs) as well as signal and coding joint kappa-deleting recombination excision circles (sjKRECs and cjKRECs, respectively) as markers of newly produced lymphocytes in 133 patients (56 primary immunodeficient and 77 malignant cases, median (range): 12 (0-62) years old). We analyzed the kinetics of TREC and KREC recovery and determined the factors that contributed to better immune recovery. KRECs became positive earlier than TRECs and increased thereafter. Younger recipient age had a favorable effect on recovery of sjKRECs and cjKRECs. Compared with BM and peripheral blood, our data suggested that cord blood (CB) provided rapid B-cell recovery. CB also provided better B-cell neogenesis in adult HCT recipients. Chronic GVHD was associated with low TRECs, but not increased sjKRECs/cjKRECs. Finally, positive sjKRECs 1 month after HCT were associated with fewer infectious episodes. Monitoring of TRECs and KRECs may serve as a useful tool for assessment of immune reconstitution post HCT.
INTRODUCTION
Hematopoietic cell transplantation (HCT) serves as a curative treatment for diseases such as hematopoietic malignancy, congenital BM failure and primary immunodeficiency (PID). Selection of a suitable donor by HLA matching and/or an appropriate conditioning regimen has improved the outcome of HCT for leukemia patients 1 and PID patients. 2, 3 Recently, successful outcomes of cord blood transplantation (CBT) and BM transplantation (BMT) have been observed even in HLAmismatched conditions. [4] [5] [6] [7] [8] Despite these improved outcomes, transplantation-related morbidities such as graft failure, GVHD and infection are still major problems that affect the prognosis and/or quality of life. Infection monitoring after HCT is important for the initiation of preemptive therapy at the appropriate time, while assessment of immune reconstitution is essential because it is considered to be associated with post-transplant infection, relapse of primary disease and OS. 9 CD4+ T-cell counts, T-cell proliferative capacity, B-cell number and serum IgG have been used as parameters of immune recovery after HCT. Recently, more direct assessment of T-and B-cell neogenesis has become feasible by analyses of T-cell receptor excision circles (TRECs) and kappa-deleting recombination excision circles (KRECs), respectively.
DNA fragments between rearranging V, D and J gene segments are deleted as circular excision products during rearrangement of the T-cell receptor gene. 10 These products are called TRECs. Quantitative detection of TRECs enables direct measurement of thymic output. The recovery of TRECs is associated with survival and infection after HCT for treatment of malignancies. [11] [12] [13] In a previous study, TREC levels were lower in patients post CBT than in those receiving BMT or PBSC transplantation (PBSCT).
Tokyo Medical and Dental University and National Defense Medical College. Informed consent was obtained in accordance with the Declaration of Helsinki.
Measurement of TREC and KREC levels TREC, sjKREC and cjKREC levels were measured by real-time PCR as described previously [15] [16] [17] [18] [19] at 1, 3 and 6 months, and yearly after HCT. RNase P was used as an internal control. Primer and probe sequences are listed in Supplementary Table I. The minimum detectable limit was 10 copies/μg DNA. TRECs or KRECs o10 copies/μg DNA were defined as negative, and TREC or KREC levels of 410 copies/μg DNA were defined as positive.
Monitoring of infections
Genomic DNA of eight human herpes virus species, BK virus, JC virus and parvovirus B19 in peripheral blood was measured by multiplex PCR and real-time PCR as described previously. 20 Adenovirus, hepatitis A virus, hepatitis B virus, hepatitis E virus, Norwalk-like virus, Coxsackie virus, ECHO virus, enterovirus, human metapneumovirus and human bocavirus were measured by real-time PCR as described elsewhere. 21 The minimum detectable limit was at least 30 copies/μg DNA.
Definitions
Patients treated with a 45 Gy single dose of TBI, 48 Gy fractionated TBI or 48 mg/kg body weight of BU in addition to other cytoreduction agents were categorized as receiving myeloablative (MA) regimens. 22 HLA typing was performed by genotyping for HLA-A, B and DRB1 loci. GVHD was graded according to standard criteria. 23 We defined the incidence of infection as having symptoms of infection with detectable pathogens and severity ⩾ grade 3 as defined in the Common Terminology Criteria for Adverse Event (CTCAE) version 4.0, National Institutes of Health and National Cancer Institute.
Statistical analysis
Recipient age, recipient sex, disease, conditioning regimen, donor age, cell source, HLA disparity, relationship, acute GVHD, chronic GVHD, and the use of steroids or antithymocyte globulin (ATG) were chosen as clinical parameters. We categorized the diseases of enrolled patients as PID or malignancy. A MA regime was evaluated in comparison with reducedintensity conditioning regimens and minimal conditioning regimens. HLAmismatched HCT was compared with 6/6 HLA-matched HCT. Acute GVHD was graded as 0-4 and divided into two groups (0-2 and 3-4). The proportion of surviving patients was estimated by the Kaplan-Meier method and compared using the log-rank test. Factors that were found to be significant (P o0.05) in univariate analysis were included in the multivariate analysis. Multivariate analyses of factors contributing to better TREC/KREC recovery were performed by excluding or including acute and chronic GVHD, steroid use, and ATG use, because these factors are post-HCT events and associated with other factors. Donor age was also excluded because it is restricted for BMT.
RESULTS
Levels of sjKRECs and cjKRECs recover faster than those of TRECs First, we evaluated the recovery of TREC, sjKREC and cjKREC levels post transplantation.
One month after HCT, TRECs, sjKRECs and cjKRECs were detectable in 17 (17.5%), 34 (35.1%),and 28 (28.9%) of 97 patients, respectively. The median copy number was low ( o10 copies/μg DNA) in all assays (Figures 1a and b) .
Eighty-two patients were examined 3 months after HCT. TRECs were positive in 15 (18.3%) patients, whereas sjKRECs and cjKRECs were positive in 57 (69.5%) and 59 (72.0%) patients, respectively (Figures 1c and d) .
TRECs became positive in 41.3% of patients at 6 months and in 66.7% of patients 1 year post HCT. SjKRECs and cjKRECs were positive in 77.8% of patients at 6 months and in 490% of patients at 1 year post HCT. The median level of TRECs was o 10 copies/μg DNA at 6 months and reached up to 1270 copies/μg DNA at 1 year. Interestingly, sjKRECs continued to increase for at least 1 year, while cjKRECs peaked at 6 months, and then started to decline (Figures 1e-h ).
The recovery of sjKREC and cjKREC levels correlated as shown in Figures 1b, d , f, and h. This finding indicates that B-cell maturation is intact once B-cell engraftment is achieved. On the other hand, a considerable number of patients exhibited B-cell neogenesis in the absence of T-cell neogenesis, especially at the early stage post HCT (Figures 1a, c, and e) .
We examined the trend of TRECs and KRECs in individual patients, of whom 71% had positive sjKRECs at 1 month and showed increased sjKRECs at 3 months. Similarly, the levels of sjKRECs detectable at 1 month increased at 6 months in 80% of the patients (Figure 2b ). On the other hand, positive TRECs at 1 month did not indicate further T-cell recovery at a later period. When we examined patients with positive TRECs at 3 months, 10 of the 11 patients had increased TREC levels at 6 months, suggesting that positive TRECs at 3 months may serve as a predictor of T-cell reconstitution after 6 months ( Figure 2a ).
Longitudinal analysis showed that the recovery course of TRECs from 1 month to 15 years post HCT is at least not inferior to CBT when compared with that of BMT and PBSCT. Compared to BMT, Abbreviations: ATG = antithymocyte globulin; CB = cord blood; MA = myeloablative; PID = primary immunodeficiency; RIC = reduced-intensity conditioning.
Factors influencing B-and T-cell neoproduction post HCT K Nakatani et al KREC levels recovered more rapidly after CBT ( Supplementary  Figures 1 and 2 ). Final sjKREC/cjKREC levels reached the levels of the age-matched control when KRECs were fully recovered (data not shown).
Younger recipient age and CB favor increased levels of sjKRECs and cjKRECs Next, we evaluated the factors that contributed to the levels of TRECs, sjKRECs and cjKRECs by regression analysis, including the factors listed in Materials and Methods (Supplementary Table II) . A younger recipient and donor age was defined as o 18 years old.
In univariate analysis, a younger recipient age was a favorable factor for increased levels of TRECs, sjKRECs or cjKRECs post HCT. In fact, only the cjKREC levels of older recipients became close to those of younger recipients at 2 years after HCT ( Figure 3 ). In BMT recipients, a younger donor age was a favorable factor for increased levels of TRECs, sjKRECs and cjKRECs (Supplementary  Table II Table II) .
A MA regime, PID, no or mild acute GVHD (grade 0-2), no chronic GVHD, no use of steroids, and no use of ATG were also favorable factors for increased levels of TRECs, sjKRECs or cjKRECs at various time points after HCT (Supplementary Table II) .
On the basis of the results obtained from the univariate analysis, the following factors were used in multivariate analysis: recipient age, disease, conditioning regimen, cell source and relationship. Our results concerning TRECs largely reconfirmed previous reports, 13, 24 indicating that a younger recipient age, no ATG use and a MA regime are associated with better TREC recovery. When focusing on B-cell recovery, we found that a younger recipient age was a favorable factor for increased levels of sjKRECs at 6 months to 2 years and cjKRECs at 6 months to 1 year after HCT. In addition, compared with BMT, CBT favored increased levels of sjKRECs at 1, 3 and 48 months. A MA regime was a favorable factor for increased levels of sjKRECs at 3 to 6 months ( Table 2) . By including acute GVHD, steroid use and ATG use in the analysis, grade 0-2 acute GVHD, no steroid use and no ATG use were identified as factors favoring better KREC recovery at various time points (Supplementary Table III ). The analysis further including chronic GVHD suggested that the condition does not affect B-cell neoproduction (Supplementary Table IV) .
We then performed multivariate analysis of a group of patients with malignancy. Compared with BM recipients, the results showed that sjKRECs and cjKRECs were more frequently detectable in CB recipients at 3 months (Supplementary Table V) . Compared with BM recipients, in adult patients of ⩾ 18 years of age (n = 44), the use of CB was a favorable factor for increased levels of sjKRECs at 1 month (Supplementary Table VI ). These data show that CB use contributes to early recovery of neogenesis. In contrast, we observed no significant difference of T-cell recovery in adult patients when CB use was compared with BM at any time point after HCT (Supplementary Figure 4) .
Positivity for sjKRECs 1 month after HCT is associated with decreased infectious episodes We next investigated whether the levels of TRECs, sjKRECs or cjKRECs were associated with the occurrence of infections. We found that positive sjKRECs or TRECs 1 month after HCT correlated with decreased infectious episodes ( Figure 5 ). Sixteen out of 34 patients who were positive for sjKRECs suffered from infections, whereas 43 of 63 patients who were negative for sjKRECs acquired infections (Figure 5b , P = 0.033).
We also examined the association between each index and the incidence of infectious episodes caused by bacteria, fungi or viruses. Although there was a tendency toward less bacterial infections in sjKREC-or cjKREC-positive groups, we found no statistical significance. Cumulative incidence of each infection did (18) (4) (18) (4) (3) (8) (3) (3) (1) (1) (2) (1) Significant unfavorable factors that contributed to the levels of TRECs, sjKRECs and cjKRECs.
Factors influencing B-and T-cell neoproduction post HCT K Nakatani et al not correlate with negative TRECs, sjKRECs or cjKRECs at 3 months after HCT (data not shown).
DISCUSSION
In this study, we examined TRECs and sjKRECs/cjKRECs in posttransplantation patients with malignancies or PID. Our data showed the following. Patients with positive sjKRECs at 1 month had increased levels of sjKRECs at 3 and 6 months, suggesting that positivity can predict sound B-cell immune reconstitution. In addition, the levels of sjKRECs and cjKRECs increased earlier than those of TRECs (Figure 1, Supplementary Figures 1 and 2) .
There have been no reports of the factors that contribute to better KREC reconstitution. Compared with BM and PB, we found that the levels of sjKRECs and cjKRECs recovered rapidly in patients who received CB. Faster B-cell reconstitution after CBT has been reported previously.
14,25 CB itself does not have high sjKREC/ cjKREC levels. Our results suggest that rapid B-cell recovery by CBT is because of B-cell neogenesis and not B-cell expansion in the periphery.
A previous study has demonstrated that sjKREC levels are the highest in o 1-year-olds and then declines with age in healthy children. 17 Thus, it is likely that younger donors have an advantage in terms of B-cell reconstitution. Our results indicated that a younger recipient age also contributed to increased levels of sjKRECs and cjKRECs.
In addition, our data showed that acute 0-2 GVHD, no steroid use and no ATG use were associated with positive sjKRECs and cjKRECs (Supplementary Tables III and IV) . These data indicate that steroid or ATG use affects not only T-cell recovery but also B-cell immune reconstitution.
As expected, patients with chronic GVHD showed significantly lower levels of TRECs at 6 months and 1 year. On the other hand, and in contrast to our expectation, we observed lower sjKRECs and cjKRECs from 3 months to 2 years in patients with chronic GVHD (Supplementary Figure 5) . This observation does not support the data of Allen et al., 26 which revealed increased numbers of B cells and expression of BAFF (B-cell-activating factor belonging to the TNF family) in patients with chronic GVHD. This discrepancy may be because the patients with chronic GVHD were on more active immunosuppressants compared with those without chronic GVHD. Additionally, there may be relatively high levels of KRECs in patients with the severe extensive type of chronic GVHD. However, we would need more patients and additional analyses of B-cell numbers and activation to reach a conclusion.
Our study suggests that patients with positivity for TRECs or sjKRECs at 1 month are less likely to develop post-transplant infections. The contribution of earlier B-cell recovery to overall immunity, especially anti-microbial immunity, needs further investigation. Patients with early B-cell neogenesis may attain early myeloid recovery. B-cells may also serve as antigenpresenting cells in addition to antibody-producing cells.
A correlation between KREC levels and prognosis has not been addressed previously. Although there was a tendency toward better survival for the KREC-positive group at 1 month, we observed no statistical significance. Further study with a larger cohort is required to determine whether the difference can be significant.
It is still unclear whether TREC levels are lower in patients post CBT than in those receiving BMT. 25 Our data focusing on adult patients showed that T-cell recovery was at least not inferior and appeared to be similar in CB and BM recipients (data not shown). On the other hand, compared with BM and PB, CB was superior for B-cell recovery. This observation suggests quantitative superiority of B-cell recovery following CBT. Further study should investigate the repertoire diversity and somatic hypermutation of B-cell receptors to evaluate qualitative differences and determine whether rapid qualitative maturation has an effect on improved outcomes. In combination with in vitro immunological data and clinical data such as long-term infection, autoimmunity and immunological findings, KRECs and TRECs may serve as useful tools for immunological monitoring after HCT.
